Cost-Effectiveness Analysis of Evolocumab for the Treatment of Dyslipidemia in the Kingdom of Saudi Arabia

BACKGROUND: Proprotein convertase subtilisin/kexin type 9 inhibitors, such as evolocumab, are cholesterol-lowering drugs effective in lowering lipid levels in high-risk patients with primary hypercholesterolemia or mixed dyslipidemia. OBJECTIVE: This study assessed the cost effectiveness of evolocum...

Descripción completa

Detalles Bibliográficos
Autores principales: Alghamdi, Ahmed, Balkhi, Bander, Altowaijri, Abdulaziz, Al-shehri, Nasser, Ralph, Lewis, Marriott, Emily-Ruth, Urbich, Michael, Aljanad, Fawaz, Aziziyeh, Rima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864041/
https://www.ncbi.nlm.nih.gov/pubmed/34582002
http://dx.doi.org/10.1007/s41669-021-00300-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864041/
https://www.ncbi.nlm.nih.gov/pubmed/34582002
http://dx.doi.org/10.1007/s41669-021-00300-8

Ejemplares similares